치료받지 않은 맨틀 세포 림프종 환자에서 자누브루티닙 + 리투시맙 대 벤다무스틴 + 리툭시맙 비교 연구 (MANGROVE)
줄기 세포 이식에 부적격한 이전에 치료받지 않은 맨틀 세포 림프종 환자에서 Zanubrutinib(BGB-3111) + Rituximab 대 Bendamustine + Rituximab을 비교하는 3상 무작위, 공개, 다기관 연구
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Goes, 네덜란드, 4462 RA
- Admiraal de Ruijter Ziekenhuis
-
Groningen, 네덜란드, 9713 GZ
- University of Medical Center Groningen (Umcg)
-
Nieuwegein, 네덜란드, 3435 CM
- St Antonius Ziekenhuis, Randd Interne Geneeskunde (F)
-
Nijmegen, 네덜란드, 6525 GA
- Albert Schweitzer Ziekenhuis
-
Rotterdam, 네덜란드, 3015 GD
- Erasmus Mc
-
The Hague, 네덜란드, 2545 CH
- Hagaziekenhuis
-
-
-
-
-
Christchurch, 뉴질랜드, 8011
- Christchurch Hospital (Canterbury Health Laboratories)
-
Tauranga, 뉴질랜드, 3112
- Tauranga Hospital
-
-
-
-
-
Tainan, 대만, 704
- National Cheng Kung University Hospital
-
Tainan, 대만, 736
- Chi Mei Hospital Liouying
-
Taipei, 대만, 114
- Tri Service General Hospital
-
-
-
-
-
Cologne, 독일, 50937
- Uniklinik Koln (Aor)
-
Heidelberg, 독일, 69120
- Universitatsklinikum Heidelberg
-
Munich, 독일, 81377
- Dept of Medicine Iii, University Hospitallmu
-
Ulm, 독일, 89081
- Universitaetsklinikum Ulm, Innere Medizin Iii
-
Wuppertal, 독일, 42283
- Petrus Krankenhaus Wuppertal
-
-
-
-
-
Moscow, 러시아 제국, 142770
- Gbuz Mmcc Kommunarka Dzm
-
-
Moscow
-
Moscow, Moscow, 러시아 제국, 125284
- Clinical Hospital, Sp Botkin
-
-
Sankt-Peterburg
-
Saint Petersburg, Sankt-Peterburg, 러시아 제국, 191024
- Fgu Russian Scientific Research Institute of Hematology and Transfusiology
-
Saint Petersburg, Sankt-Peterburg, 러시아 제국, 194291
- Leningrad Regional Clinic and Hospital
-
-
-
-
-
Bucharest, 루마니아, 022328
- Institutul Clinic Fundeni
-
Iași, 루마니아, 700483
- Institutul Regional de Oncologie Iasi
-
-
-
-
California
-
Orange, California, 미국, 92868
- Chao Family Comprehensive Cancer Center
-
-
Illinois
-
Chicago, Illinois, 미국, 60612
- Rush University Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215-5400
- Beth Israel Deaconess Medical Center (Bidmc)
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- University of Michigan Health System
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89169
- Comprehensive Cancer Centers of Nevada
-
-
New York
-
New York, New York, 미국, 10029
- Icahn School of Medicine At Mount Sinai
-
Westbury, New York, 미국, 11590
- Clinical Research Alliance, Inc
-
-
Oregon
-
Portland, Oregon, 미국, 97213
- Providence Portland Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15224
- West Penn Hospital
-
-
Texas
-
Houston, Texas, 미국, 77030-4009
- The University of Texas Md Anderson Cancer Center
-
Lubbock, Texas, 미국, 79410
- Joe Arrington Cancer Research and Treatment Center
-
-
Washington
-
Seattle, Washington, 미국, 98109
- Seattle Cancer Care Alliance
-
-
-
-
-
Bruges, 벨기에, 8000
- Az Sint Jan Brugge
-
Brussels, 벨기에, 1090
- Universitair Ziekenhuis Brussel
-
Edegem, 벨기에, 2650
- Uz Antwerpen
-
Kortrijk, 벨기에, 8500
- Az Groeninge Campus Loofstraat
-
Liège, 벨기에, 4000
- Centre Hospitalier Universitaire (Chu) de Liege Site Du Sart Tilman
-
Yvoir, 벨기에, 5530
- Centre Hospitalier Universitaire Universite Catholique de Louvain Site Godinne
-
-
-
-
-
Barcelona, 스페인, 08035
- Hospital Universitario Vall Dhebron
-
Barcelona, 스페인, 08916
- Ico Hug Trias I Pujol
-
Barcelona, 스페인, 08908
- Institut Catala Doncologia
-
Girona, 스페인, 17007
- Ico Girona
-
Madrid, 스페인, 28046
- Hospital Universitario La Paz
-
Madrid, 스페인, 28040
- Start Madrid Fundacion Jimenez Diaz
-
Madrid, 스페인, 28033
- Md Anderson Cancer Center Madrid Spain
-
Madrid, 스페인, 28009
- Hospital Universitario Gregorio Maranon
-
Málaga, 스페인, 29010
- Hospital Regional Universitario de Malaga
-
Seville, 스페인, 41013
- Hospital Universitario Virgen Del Rocio
-
-
-
-
-
Cork, 아일랜드, t12DC4A
- Cork University Hospital
-
Dublin, 아일랜드, D7
- Mater Misericordiae University Hospital
-
Dublin, 아일랜드, D8
- St Jamess Hospital
-
Galway, 아일랜드, H91 YR71
- University Hospital Galway
-
Limerick, 아일랜드, V94F858
- University Hospital Limerick
-
Waterford, 아일랜드, X91 ER8E
- University Hospital Waterford
-
-
-
-
-
Abergavenny, 영국, NP7 7EG
- Aneurin Bevan University Health Board
-
Birmingham, 영국, B9 5SS
- Birmingham Heartlands Hospital
-
Dudley, 영국, DY1 2HQ
- Russells Hall Hopsital
-
Sutton, 영국, SM2 5PT
- Royal Marsden Nhs Foundation Royal Marsden Hospital
-
-
-
-
-
Linz, 오스트리아, 4020
- Ordensklinikum Linz Gmbh Elisabethinen
-
Salzburg, 오스트리아, 5020
- Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg
-
Vienna, 오스트리아, 1090
- Medical University Vienna Oncology
-
-
-
-
-
Cherkasy, 우크라이나, 18009
- Cherkasy Regional Oncology Dispensary
-
Dnipro, 우크라이나, 49102
- Municipal Non Profit Enterprise City Clinical Hospital
-
Kiev, 우크라이나, 3022
- National Cancer Institute
-
Lviv, 우크라이나, 79044
- Si Institute of Blood Pathology and Transfusion Medicine Nams of Ukraine, Hematology Department
-
-
-
-
-
Alessandria, 이탈리아, 15121
- Azienda Ospedaliera Nazionale Ssantonio E Biagio E Cesare Arrigo
-
Bologna, 이탈리아, 40138
- Policlinico Sorsola Malpighi, Aou Di Bologna
-
Genova, 이탈리아, 16132
- Azienda Ospedaliera Universitaria San Martino
-
Milan, 이탈리아, 20162
- Niguarda Cancer Center Division of Hematology
-
Novara, 이탈리아, 28100
- Aou Maggiore Della Carita
-
Palermo, 이탈리아, 90146
- Aoor Villa Sofia Cervello
-
Pisa, 이탈리아, 56126
- Aou Pisana, Stabilimento Di Santa Chiara
-
Ravenna, 이탈리아, 48121
- Unita Di Ematologia, Dipartimento Di Ematologia Ed Oncologia
-
Reggio Emilia, 이탈리아, 42123
- Azienda Unita Sanitaria Locale Irccs
-
Roma, 이탈리아, 00161
- Universita Degli Studi La Sapienza
-
Siena, 이탈리아, 53100
- Aou Senese Policlinico Santa Maria Alle Scotte
-
Torino, 이탈리아, 10126
- Ao Citta Della Salute E Della Scienza Di Torino Presidio O
-
Verona, 이탈리아, 37142
- University of Verona
-
-
-
-
-
Yokohama, 일본, 221-0855
- Yokohama Municipal Citizens Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, 일본, 460-0001
- National Hospital Organization Nagoya Medical Center
-
Toyohashi, Aichi-ken, 일본, 441-8570
- Toyohashi Municipal Hospital
-
-
Chiba
-
Chiba, Chiba, 일본, 260-8717
- Chiba Cancer Center
-
-
Fukuoka
-
Kurume, Fukuoka, 일본, 830-0011
- Kurume University Hospital
-
-
Hiroshima
-
Hiroshima, Hiroshima, 일본, 730-8619
- Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
-
-
Kanagawa
-
Yokohama, Kanagawa, 일본, 241-8515
- Kanagawa Cancer Center
-
-
Kumamoto
-
Kumamoto, Kumamoto, 일본, 860-0008
- National Hospital Organization Kumamoto Medical Center
-
-
Kyoto
-
Kyoto, Kyoto, 일본, 602-8566
- University Hospital, Kyoto Prefectural Univ of Medicine
-
-
Miyagi
-
Sendai, Miyagi, 일본, 980-8574
- Tohoku University Hospital
-
-
Okayama-ken
-
Kurashikishi, Okayama-ken, 일본, 710-8602
- Kurashiki Central Hospital
-
Okayama, Okayama-ken, 일본, 701-1192
- National Hospital Organization Okayama Medical Center
-
-
Osaka
-
Osaka, Osaka, 일본, 545-8586
- Osaka Metropolitan University Hospital
-
Osakashi, Osaka, 일본, 543-8555
- Osaka Red Cross Hospital
-
-
Tokyo
-
Chuoku, Tokyo, 일본, 104-0045
- National Cancer Center Hospital
-
Tokyo, Tokyo, 일본, 113-8519
- Tokyo Medical and Dental University Hospital
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100044
- Peking University Peoples Hospital
-
Beijing, Beijing Municipality, 중국, 100050
- Beijing Friendship Hospital, Capital Medical University
-
-
Fujian
-
Fuzhou, Fujian, 중국, 350001
- Fujian Medical University Union Hospital
-
Quanzhou, Fujian, 중국, 362000
- Quanzhou First Affliated Hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, 중국, 510080
- Guangdong Provincial Peoples Hospital
-
Guangzhou, Guangdong, 중국, 510515
- Nanfang Hospital of Southern Medical University
-
Guangzhou, Guangdong, 중국, 510060
- Sun Yat Sen University Cancer Center
-
-
Heilongjiang
-
Harbin, Heilongjiang, 중국, 150000
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, 중국, 450000
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, 중국, 430030
- Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, 중국, 410013
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, 중국, 210029
- Jiangsu Province Hospital
-
Nanjing, Jiangsu, 중국, 210008
- Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
-
Xuzhou, Jiangsu, 중국, 221000
- The Affiliated Hospital of Xuzhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국, 330006
- The First Affiliated Hospital of Nanchang University Branch Donghu
-
-
Jilin
-
Changchun, Jilin, 중국, 130021
- The First Hospital of Jilin University
-
Changchun, Jilin, 중국, 130021
- Jilin Cancer Hospital
-
-
Liaoning
-
Shenyang, Liaoning, 중국, 110004
- Shengjing Hospital of China Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200000
- Fudan University Shanghai Cancer Center
-
Shanghai, Shanghai Municipality, 중국, 200120
- Shanghai East Hospital
-
-
Sichuan
-
Chengdu, Sichuan, 중국, 610041
- West China Hospital, Sichuan University
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, 중국, 300060
- Tianjin Medical University Cancer Institute and Hospital
-
Tianjin, Tianjin Municipality, 중국, 300020
- Institute of Hematology and Hospital of Blood Disease
-
-
Xinjiang
-
Ürümqi, Xinjiang, 중국, 830000
- Affiliated Cancer Hospital of Xinjiang Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, 중국, 310022
- Zhejiang Cancer Hospital
-
Hangzhou, Zhejiang, 중국, 310003
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Ningbo, Zhejiang, 중국, 315000
- Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital)
-
-
-
-
Ontario
-
Ottawa, Ontario, 캐나다, K1H 8M2
- The Ottawa Hospital
-
-
Quebec
-
Sherbrooke, Quebec, 캐나다, J1H 5N4
- Ciusss de Lestrie Chus
-
-
-
-
-
Ankara, 터키 (Türkiye), 06620
- Dr Abdurrahman Yurtaslan Oncology Teaching and Research Hospital
-
Ankara, 터키 (Türkiye), 6500
- Gazi University
-
Ankara, 터키 (Türkiye), 06700
- Hematoloji Ve Hematolik Onkoloji Tani Ve Tedavi Merezi
-
Edirne, 터키 (Türkiye), 22030
- Tr Trakya University Health Research and Application Center (Hospital)
-
Istanbul, 터키 (Türkiye), 34365
- Vkv American Hospital
-
Mersin, 터키 (Türkiye), 33000
- Mersin Universitesi Tip Fakultesi Hastanesi
-
-
-
-
-
Lisbon, 포르투갈, 1099-023
- Instituto Portugues Oncologia de Lisboa Francisco Gentil, Epe
-
Lisbon, 포르투갈, 1649-035
- Chuln Hospital de Santa Maria
-
Porto, 포르투갈, 4099-001
- Centro Hospitalar Universitario Porto
-
Porto, 포르투갈, 4200-072
- Instituto Portugues de Oncologia Do Porto Francisco Gentil, Epe
-
-
-
-
-
Bydgoszcz, 폴란드, 85-168
- Szpital Uniwersytecki Nr Im Dr Jana Biziela
-
Chorzów, 폴란드, 41-503
- Silesian Healthy Blood Clinic
-
Gdansk, 폴란드, 80-952
- Uniwersyteckie Centrum Kliniczne
-
Gdask, 폴란드, 80-219
- Copernicus Podmiot Leczniczy Sp Z Oo Wojewodzkie Centrum Onkologii
-
Gdynia, 폴란드, 81-519
- Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia
-
Krakow, 폴란드, 30-727
- Pratia McM Krakow
-
Legnica, 폴란드, 59-220
- Wojewodzki Szpital Specjalistyczny W Legnicy
-
Lodz, 폴란드, 93-510
- Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
-
Lublin, 폴란드, 20-090
- Centrum Onkologii Ziemi Lubelskiej
-
Warsaw, 폴란드, 02-776
- Instytut Hematologii I Transfuzjologii W Warszawie
-
Wałbrzych, 폴란드, 58-309
- Specjalistyczny Szpital Im Dr Alfreda Sokolowskiego
-
Wroclaw, 폴란드, 50-556
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
-
Bordeaux, 프랑스, 33076
- Centre de Lutte Contre Le Cancer Institut Bergonie
-
Brest, 프랑스, 29200
- Chru de Brest Hospital Morvan
-
Dijon, 프랑스, J4V 2H1
- Chu Dijon
-
Grenoble, 프랑스, 38043
- Chu Grenoble Alpes
-
Le Mans, 프랑스, 72037
- Centre Hospitalier Le Mans
-
Lille, 프랑스, 59000
- Hopital Claude Huriez Chu Lille
-
Marseille, 프랑스, 13009
- Institut Paoli Calmettes
-
Nantes, 프랑스, 44093
- Centre Hospitalier Universitaire Nantes Hotel Dieu
-
Paris, 프랑스, 75005
- Institut Curie
-
Paris, 프랑스, 75015
- Necker University Hospital
-
PierreBenite, 프랑스, 69495
- Chu Hopital Lyon Sud
-
Poitiers, 프랑스, 86000
- Centre Hospitalier Universitaire de Poitier Hopital de La Miletrie Hopital Jean Bernard
-
Quimper, 프랑스, 29000
- Ch Cornouaille
-
Toulouse, 프랑스, 31059
- Iuc Toulouse Oncopole
-
-
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, 호주, 2605
- Canberra Hospital
-
-
New South Wales
-
Concord, New South Wales, 호주, 2139
- Concord Repatriation General Hospital
-
Cudgen, New South Wales, 호주, 2487
- The Tweed Valley Hospital
-
Darlinghurst, New South Wales, 호주, 2010
- Saint Vincents Hospital Sydney
-
Gosford, New South Wales, 호주, 2250
- Gosford Hospital
-
Waratah, New South Wales, 호주, 2298
- Calvary Mater Newcastle
-
-
Queensland
-
Birtinya, Queensland, 호주, 4575
- Sunshine Coast Hospital and Health Service
-
South Brisbane, Queensland, 호주, 4101
- Icon Cancer Foundation
-
-
South Australia
-
Bedford PK, South Australia, 호주, 5042
- Flinders Medical Centre
-
-
Tasmania
-
Hobart, Tasmania, 호주, 7000
- Royal Hobart Hospital
-
-
Victoria
-
Clayton, Victoria, 호주, 3168
- Monash Health
-
Fitzroy, Victoria, 호주, 3065
- St Vincents Hospital Melbourne
-
Frankston, Victoria, 호주, 3199
- Peninsula Private Hospital
-
Geelong, Victoria, 호주, 3220
- Barwon Health the Geelong Hospital
-
-
Western Australia
-
Perth, Western Australia, 호주, 6000
- Royal Perth Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- ≥70 years of age at the time of informed consent, OR ≥60 and <70 years of age with comorbidities precluding autologous stem cell transplantation
- Histologically confirmed diagnosis of MCL
- No prior systemic treatments for MCL
- Measurable disease by CT/MRI
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Adequate marrow and organ function
Key Exclusion Criteria:
- Known central nervous system involvement by lymphoma
- Participants for whom the goal of therapy is tumor debulking prior to stem cell transplant
- Clinically significant cardiovascular disease
- History of severe bleeding disorder
- Unable to swallow capsules or disease significantly affecting gastrointestinal function
- Active fungal, bacterial and/or viral infection requiring systemic therapy
- Requires ongoing treatment with a strong CYP3A inhibitor or inducer
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Arm A: zanubrutinib plus rituximab
Participants will receive zanubrutinib plus rituximab, followed by zanubrutinib monotherapy until Independent Review Committee (IRC)-confirmed disease progression. |
Administered as two 80 mg capsules by mouth twice a day
다른 이름들:
Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6 |
|
활성 비교기: Arm B: bendamustine plus rituximab
Participants will receive bendamustine plus rituximab, followed by observation. |
Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6 Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6 |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free survival (PFS) determined by independent central review
기간: Up to approximately 7 years
|
PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first. |
Up to approximately 7 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PFS by investigator assessment
기간: Up to approximately 7 years
|
PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first. |
Up to approximately 7 years
|
|
Overall response rate (ORR)
기간: Up to approximately 7 years
|
ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), determined by independent central review and by investigator assessment. |
Up to approximately 7 years
|
|
Duration of response (DOR)
기간: Up to approximately 7 years
|
DOR, as determined by independent central review and by investigator assessment, and defined as the time from the date that response criteria are first met to the date that disease progression is objectively documented or death, whichever occurs first. |
Up to approximately 7 years
|
|
Overall survival (OS)
기간: Up to approximately 7 years
|
OS is defined as the time from randomization to the date of death due to any reason. |
Up to approximately 7 years
|
|
Time to Response (TTR)
기간: Up to approximately 7 years
|
TTR, as determined by independent central review and by investigator assessment, and defined as the time from randomization to the first documentation of response. |
Up to approximately 7 years
|
|
Rate of complete response (CR) or complete metabolic response
기간: Up to approximately 7 years
|
Rate of CR or complete metabolic response is defined as the percentage of participants who achieve a CR or complete metabolic response, determined by independent central review and by investigator assessment. |
Up to approximately 7 years
|
|
Participant-reported outcomes (PROs) as assessed by the European Quality of Life 5-Dimension 5 Level Questionnaire (EQ-5D-5L)
기간: Up to approximately 7 years
|
EuroQoL-Five Dimensions, Five Levels (EQ-5D-5L) is a generic, self-reported measure of utility that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). The descriptive system involves five health dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Participants may choose from the following response levels: no problems=1; slight problems=2; moderate problems=3; severe problems=4; and unable to/extreme problems=5. Higher values indicate worst health. |
Up to approximately 7 years
|
|
PROs as assessed by the European Organization for Research on Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
기간: Up to approximately 7 years
|
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best). |
Up to approximately 7 years
|
|
Number of participants with adverse events and serious adverse events
기간: Up to approximately 7 years
|
Number of participants with adverse events and serious adverse events, including laboratory values, vital signs, and physical examination findings. |
Up to approximately 7 years
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Study Director, BeOne Medicines
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
- 신생물
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 림프계 질환
- 림프 증식 장애
- 면역증식성 장애
- 림프종
- 헴 및 림프병
- 림프종, 비호지킨
- 림프종, 외투세포
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물
- Benzimidazoles
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 탄화수소
- 산, acyclic
- 카르 복실 산
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 질소 머스타드 화합물
- 겨자 화합물
- 탄화수소, 할로겐화
- 부티레이트
- 항체, 모노클로 날, 뮤린 유래
- 벤다무스틴 염산염
- 리툭시맙
- Zanubrutinib
기타 연구 ID 번호
기타 연구 ID 번호
- BGB-3111-306
- 2019-000413-36 (EudraCT 번호)
- CTR20211594 (레지스트리 식별자: ChinaDrugTrials)
- 2023-509908-15-00 (씨티스)
- 2023 (미국 NIH 보조금/계약)
- 2019 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
IPD 공유 기간
See plan description
IPD 공유 액세스 기준
See plan description
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .